ArticleBMC cancer2026

The prognostic value of maintaining minimal residual disease status in patients with acute myeloid leukaemia receiving azacitidine-based therapy.

Jun-Fang Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.